m+Medelevator.RU
← Поиск публикаций
Medical decision making : an international journal of the Society for Medical Decision Making · 2026

Comparing and Selecting Network Meta-Analysis Models for Cost-Effectiveness Analysis of Anticancer Drugs.

СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhao Mingye, Shao Taihang, Shao Hanqiao, Li Hao, Tang Wenxi

Аннотация

OBJECTIVES: To systematically evaluate how survival estimates from network meta-analyses (NMA) models affect oncology cost-effectiveness analysis (CEA) results, particularly under different proportional hazards (PH) assumptions and extrapolation strategies.

METHODS: A total of 19 time-to-event NMA models were evaluated in this analysis, encompassing Cox proportional hazards (Cox-PH), fractional polynomial (FP), Royston-Parmar (RP) models, piecewise exponential (PWE), generalized gamma (Gengamma), and parametric survival models (PSM), with 2 extrapolation strategies for non-PH models: a constant-tail hazard ratio (Fixed-HR) and a parametric extrapolation approach (Varying-HR). NMA model performance was assessed via relative error (RE) by comparing CEA outcomes derived from NMA-based survival estimates with those from head-to-head clinical data.

RESULTS: Fifteen CEA models were conducted. The selection of the NMA model exerted a greater influence on CEA outcomes than traditional model parameters (ie, costs or utilities). RP models appeared to perform best, while PWE, second-order FP, and Gengamma models tended to perform comparatively worse. Fixed-HR extrapolation approaches generally yielded more accurate long-term projections than Varying-HR methods did, particularly under non-PH conditions. Violations of the PH assumption substantially increased uncertainty, especially for non-PH models. Notably, the choice of NMA model led to reversals in cost-effectiveness conclusions in up to one-third of the evaluated CEA cases.

CONCLUSIONS: NMA model choice substantially influences oncology CEA outcomes. Underutilized but well-performing RP models show strong potential for broader application. Fixed-HR extrapolation was preferred in our study. These findings are context specific, and further validation is needed. When PH assumption is violated, the selection of non-PH models requires greater caution. Our findings may offer insights to support future refinements in CEA methodological guidance.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты